

## **Zydus receives tentative approval from the USFDA for Linagliptin and Metformin Hydrochloride Tablets**

---

*Ahmedabad, 12 October, 2018*

Zydus Cadila has received the tentative approval from the USFDA to market Linagliptin and Metformin Hydrochloride Tablets (US RLD – Jentaducto<sup>®</sup> Tablets), 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1,000 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. It is used along with diet and exercise to improve control of blood sugar levels in adults with type 2 diabetes mellitus.

The group now has 221 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*